Lannett (NYSE:LCI) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, January 30th.
Lannett (NYSE:LCI) last released its quarterly earnings results on Monday, November 6th. The company reported $0.60 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.08. Lannett had a return on equity of 18.23% and a net margin of 6.67%. The firm had revenue of $155.00 million for the quarter, compared to analyst estimates of $153.62 million. During the same quarter last year, the company posted $0.77 earnings per share. The business’s revenue was down 4.1% on a year-over-year basis. On average, analysts expect Lannett to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Lannett (NYSE:LCI) opened at $23.05 on Tuesday. The company has a current ratio of 2.52, a quick ratio of 1.90 and a debt-to-equity ratio of 1.44. Lannett has a twelve month low of $14.90 and a twelve month high of $30.35. The stock has a market capitalization of $867.09, a PE ratio of 8.55, a P/E/G ratio of 1.49 and a beta of 2.85.
A number of equities analysts recently issued reports on the company. Zacks Investment Research lowered Lannett from a “buy” rating to a “hold” rating in a report on Wednesday, December 13th. Oppenheimer reissued a “hold” rating on shares of Lannett in a report on Monday, December 11th. ValuEngine raised Lannett from a “hold” rating to a “buy” rating in a report on Saturday, November 25th. Finally, BMO Capital Markets lifted their price objective on Lannett from $20.00 to $22.00 and gave the company a “market perform” rating in a report on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $23.60.
Lannett Company Profile
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.